"Cost-Benefit Analysis" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A method of comparing the cost of a program with its expected benefits in dollars (or other currency). The benefit-to-cost ratio is a measure of total return expected per unit of money spent. This analysis generally excludes consideration of factors that are not measured ultimately in economic terms. Cost effectiveness compares alternative ways to achieve a specific set of results.
| Descriptor ID |
D003362
|
| MeSH Number(s) |
N03.219.151.125
|
| Concept/Terms |
Cost-Benefit Analysis- Cost-Benefit Analysis
- Analyses, Cost-Benefit
- Analysis, Cost-Benefit
- Cost-Benefit Analyses
- Cost Benefit Analysis
- Analyses, Cost Benefit
- Analysis, Cost Benefit
- Cost Benefit Analyses
Cost-Utility Analysis- Cost-Utility Analysis
- Analyses, Cost-Utility
- Analysis, Cost-Utility
- Cost Utility Analysis
- Cost-Utility Analyses
Economic Evaluation- Economic Evaluation
- Economic Evaluations
- Evaluation, Economic
- Evaluations, Economic
Marginal Analysis- Marginal Analysis
- Analyses, Marginal
- Analysis, Marginal
- Marginal Analyses
Cost Benefit- Cost Benefit
- Costs and Benefits
- Benefits and Costs
|
Below are MeSH descriptors whose meaning is more general than "Cost-Benefit Analysis".
Below are MeSH descriptors whose meaning is more specific than "Cost-Benefit Analysis".
This graph shows the total number of publications written about "Cost-Benefit Analysis" by people in this website by year, and whether "Cost-Benefit Analysis" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 2 | 2 |
| 1996 | 0 | 2 | 2 |
| 1997 | 0 | 6 | 6 |
| 1998 | 0 | 7 | 7 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 9 | 9 |
| 2001 | 1 | 6 | 7 |
| 2002 | 0 | 7 | 7 |
| 2003 | 0 | 10 | 10 |
| 2004 | 1 | 8 | 9 |
| 2005 | 1 | 9 | 10 |
| 2006 | 0 | 11 | 11 |
| 2007 | 0 | 14 | 14 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 8 | 8 |
| 2010 | 0 | 12 | 12 |
| 2011 | 0 | 10 | 10 |
| 2012 | 0 | 19 | 19 |
| 2013 | 0 | 16 | 16 |
| 2014 | 4 | 11 | 15 |
| 2015 | 5 | 27 | 32 |
| 2016 | 3 | 22 | 25 |
| 2017 | 8 | 18 | 26 |
| 2018 | 5 | 18 | 23 |
| 2019 | 5 | 23 | 28 |
| 2020 | 6 | 23 | 29 |
| 2021 | 4 | 21 | 25 |
| 2022 | 1 | 10 | 11 |
| 2023 | 1 | 11 | 12 |
| 2024 | 7 | 9 | 16 |
| 2025 | 3 | 11 | 14 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cost-Benefit Analysis" by people in Profiles.
-
Corrected T1 (cT1) is the most appropriate diagnosis and monitoring tool for widespread adoption of resmetirom treatment in the United States. J Med Econ. 2025 Dec; 28(1):1370-1387.
-
Capivasertib cost-effectiveness in treating advanced breast cancer: A US health care perspective. J Manag Care Spec Pharm. 2025 Sep; 31(9):900-908.
-
RCT comparing the clinical efficacy and costs of two tissue approximation devices in the closure of large post-endoscopic resection defects. Surg Endosc. 2025 Aug; 39(8):5442-5453.
-
Using a Markov Model and Real-World Evidence to Identify the Most Cost-Effective Cholesterol Treatment Escalation Threshold for the Secondary Prevention of Cardiovascular Disease. Appl Health Econ Health Policy. 2025 Sep; 23(5):869-883.
-
Value-based care in allergy-immunology: Beyond the quality-adjusted life year. Allergy Asthma Proc. 2025 May 01; 46(3):165-167.
-
SCS for CRPS: A Review of Cost-Effectiveness Models. Curr Pain Headache Rep. 2025 Apr 21; 29(1):75.
-
Unveiling the cost-effectiveness of bariatric surgery: insights from a matched cohort study. Surg Obes Relat Dis. 2025 09; 21(9):987-995.
-
A Systematic Review of Cost-Effectiveness Studies on Pancreatic Cancer Screening. Curr Oncol. 2025 Apr 11; 32(4).
-
Is online hemodiafiltration a cost-effective alternative to conventional hemodialysis? Kidney Int. 2025 Apr; 107(4):602-605.
-
A Hemophilia Joint Health Score-Based Model for the Economic Evaluation of Hemophilia A Prophylaxis Interventions. Pharmacoeconomics. 2025 Jul; 43(7):765-778.